Problematic patents

Given that Novartis AG’s anti-cancer drug Glivec is patented in its current form in many countries from the US to China and several in Europe, it is hardly surprising that Novartis’s India chairman has reacted to the Supreme Court’s rejection of its patent application by saying big pharma is unlikely to want to invest in India. Like many others, Novartis argued India’s patent regime, particularly Section 3(d) of the Patents Act, was not compliant with the global TRIPS agreement.

Read Full Story>>